Labcorp Holdings Inc. (LH) Cash Flow Statement

The wide quarterly swings in OCF/NI, from -0.13 in 2024Q1 to 5.42 in 2024Q4, appear driven by working capital swings rather than earnings quality issues. The 2026Q2 ratio of 1.49, with net income of $298.7M and OCF of $445.5M, suggests that reported earnings are being backed by cash generation, but the pattern is inconsistent. Investors should monitor whether the recent stabilization in conversion ratios reflects a structural improvement or merely a favorable timing quarter.

The FCF trajectory shows a clear recovery from the negative FCF in 2024Q1 and 2025Q1, with 2026Q2 FCF of $313.9M representing a significant improvement. However, the 2026Q1 FCF of $70.5M was weak, and the overall trend is uneven. The gap between FCF and net income is notable: in 2026Q2, FCF exceeded net income by $15.2M, but in 2026Q1, FCF was only 25% of net income, highlighting the lumpy nature of working capital. This suggests that while the core business is generating cash, the timing of collections and payments creates volatility that investors should factor into valuation.

The capital expenditure ratio has remained relatively stable, with a slight decline from 4.2% in 2024Q1 to 3.5% in 2026Q2, implying that LH is not significantly increasing its capital intensity. However, the absolute CapEx levels, around $120-130M per quarter, are substantial and likely include both maintenance and growth components. Given the company's focus on automation to reduce labor costs, the maintenance vs. growth split is critical; if a large portion is maintenance, the FCF generation may be less robust than it appears. The stable ratio suggests management is disciplined in capital allocation, but the need to replace aging lab equipment and invest in new testing capabilities will likely keep CapEx elevated.

The working capital changes are highly volatile, with negative changes in most quarters, indicating that cash is being tied up in receivables or inventory. The 2026Q2 negative change of -$198.0M, despite strong net income, suggests that collections may be slowing or that payables are being managed more aggressively. The pattern of large negative working capital changes in Q1 of each year (2024Q1: -$468.3M, 2025Q1: -$444.7M, 2026Q1: -$352.9M) points to a seasonal build-up in receivables, possibly due to patient deductibles and insurance timing. This seasonality is a critical factor for modeling cash flow, as it depresses Q1 OCF and inflates Q4 OCF.

The capital deployment strategy is clearly oriented toward shareholder returns and acquisitions. Buybacks have been substantial, with $353.8M in 2026Q2 alone, and cumulative buybacks over the last four quarters exceed $700M. Acquisitions have also been a consistent use of cash, with net outflows in every quarter, indicating an ongoing bolt-on M&A strategy. Dividends are stable and modest, growing slightly from $60.1M in 2024Q4 to $58.7M in 2026Q2, but the yield remains low. The heavy buyback activity, funded by operating cash flow, suggests management believes the stock is undervalued, but it also reduces the cash available for debt reduction or other investments. Investors should monitor whether this pace is sustainable given the working capital volatility.